Biomarker Clinical Trial
Official title:
A Bidirectional Cohort Study of COMMD10 Expression in Tumor Tissues for Predicting Radiosensitivity
Radiotherapy is one of the main treatments for malignant tumors, and according to authoritative estimates, about 70% of patients with malignant tumors should receive radiotherapy. However, radiation resistance limits its application and clinical curative effect. To find suitable radiation resistance markers and identify patients with radiation resistance, early part of the patients with appropriate radiotherapy sensitization agent or choose other more efficient and low toxicity of treatment, for improving the prognosis of patients, improve the quality of survival is of great significance, it is also the difficult point in the present study. However, there are no effective biomarkers to predict radiosensitivity. Through our previous basic research and analysis of clinical tumor tissues, we have found that the low expression of copper metabolism domain protein 10 (COMMD10) is associated with radioresistance, and COMMD10 is an effective marker for predicting radiosensitivity. We planned to conduct a single-center, prospective cohort study to verify the reliability of COMMD10 as a predictive marker for radiosensitivity in pan-cancer patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04681040 -
Risk Stratification of COVID-19 Using Urine Biomarkers
|
||
| Recruiting |
NCT05372172 -
Tennessee Alzheimer's Project
|
||
| Recruiting |
NCT06096766 -
the Correlation Between Ovarian Function and Serum Biomarkers
|
||
| Completed |
NCT04103632 -
Screening and Diagnosing Exercise-induced Bronchoconstriction in Recreational Young Athletes (12-18 y)
|
N/A | |
| Completed |
NCT01159730 -
Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers
|
Phase 2 | |
| Completed |
NCT04507724 -
The Use of Biochemical Analyzes to Monitor the Development of Wounds
|
||
| Completed |
NCT06338111 -
Interventions Meant to Improve the Outcome of Critical Care Patients in the ED
|
||
| Active, not recruiting |
NCT05027165 -
Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
|
||
| Not yet recruiting |
NCT02931136 -
Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging
|
Phase 4 | |
| Not yet recruiting |
NCT03739892 -
Biomarkers to Predict Gain From Therapy in Motor Stroke
|
N/A | |
| Recruiting |
NCT03801681 -
ARrhythmias in MYocarditis
|
||
| Recruiting |
NCT05372965 -
The Effects of Smoking on miRNA-223 Before-After Non-Surgical Periodontal Therapy in Patients With Stage-3, Grade-B Periodontitis
|
N/A | |
| Completed |
NCT04772495 -
miRNA Biomarkers in Multiple Sclerosis
|
||
| Active, not recruiting |
NCT06178692 -
Validation Study of a Serum-miRNA Signature in Glioma Patients.
|
||
| Recruiting |
NCT04931537 -
Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
|
||
| Recruiting |
NCT05090410 -
Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate
|
Phase 3 | |
| Not yet recruiting |
NCT05764356 -
Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II
|
||
| Recruiting |
NCT02201446 -
The Role of Circulating Soluble CD74 in Acute Lung Injury
|
N/A | |
| Not yet recruiting |
NCT05752890 -
A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma
|